

***Fiscal Year 2021 Rare Cancers Research Program (RCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Concept Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-RCRP-CA</p>	<p>Investigators at or above the level of postdoctoral fellow.</p>	<ul style="list-style-type: none"> • Supports innovative, high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers. Proof-of-concept is the anticipated outcome. • Reviewers will be blinded to the identity of the Principal Investigator, collaborators, and their organization(s). • Submission must address at least one of the FY21 Focus Areas of Biology and Etiology, Research Model, and/or Therapy. • Preliminary data are not required. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • Maximum funding of \$100,000 for direct costs (plus indirect costs) • Maximum period of performance is 1 year 	<p>Pre-Application (Letter of Intent): July 13, 2021 5:00 p.m. Eastern time (ET)</p> <p>Application: August 13, 2021 11:59 p.m. ET</p>

***Fiscal Year 2021 Rare Cancers Research Program (RCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-RCRP-IDA</p>	<p>Investigators at or above the level of Assistant Professor.</p>	<ul style="list-style-type: none"> • Preproposal submission is required; application submission is by invitation only. • Supports innovative, high-risk/high-reward research with the potential to yield impactful data in the rare cancer field. • <i>Preliminary data with disease-specific rationale (including correlatives in existing trials) to support the feasibility of the research hypotheses and research approaches are required.</i> • Submission must address at least one of the FY21 Focus Areas of Biology and Etiology, Research Model, and/or Therapy. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • Maximum funding of \$350,000 for direct costs (plus indirect costs) • Maximum period of performance is 3 years 	<p>Pre-Application (Preproposal): July 13, 2021 5:00 p.m. ET</p> <p>Application: October 15, 2021 11:59 p.m. ET</p>
<p>Resource and Community Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p>	<p>Investigators at or above the level of Assistant Professor.</p>	<ul style="list-style-type: none"> • Preproposal submission is required; application submission is by invitation only. • Emphasis on research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family 	<ul style="list-style-type: none"> • Maximum funding of \$600,000 for direct costs (plus indirect costs) • Maximum period of performance is 3 years 	<p>Pre-Application (Preproposal): July 13, 2021 5:00 p.m. ET</p> <p>Application: October 15, 2021 11:59 p.m. ET</p>

***Fiscal Year 2021 Rare Cancers Research Program (RCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<u>W81XWH-21-RCRP-RCDA</u>		<p>members, caregivers, clinicians, and other members of the rare cancers community.</p> <ul style="list-style-type: none"> • Supports platform development or infrastructure that can be applied to multiple rare cancers. • Preliminary data are not required but may be included (translational research and clinical studies may be included). • Submission must address the Platform Development Focus Area. • Clinical trials are not allowed. 		